Boddie A W, Urist M M, Chee D O, Holmes E C, Morton D L
Int J Cancer. 1975 Dec 15;16(6):1035-41. doi: 10.1002/ijc.2910160618.
KCl extracts of Melanoma 14, a human melanoma cell line grown in chemically defined serum-free medium, inhibited leukocyte migration in 19/36 (53%) patients with malignant melanoma. Only 4/23 (17%) controls with non-melanoma malignancies and 4/25 (14%) normal subjects with no history of cancer were similarly inhibited. Only 2/27 melanoma patients tested against KCl extracts of normal muscle tissue excised from the donor of Melanoma 14 were significantly inhibited. Patients with Stage I (localized) melanoma and patients with Stage III (generalized) melanoma reacted with roughly equal frequency but the number of patients in each group was too small for meaningful statistical analysis. Leukocytes from the donor of Melanoma 14 were tested in a completely autologous system against extracts of Melanoma 14 tissue culture cells and extracts of autologous muscle and were specifically inhibited by the Melanoma 14 tissue culture extract (Migration Index = 0.67) but not by the extract of normal muscle (Migration Index = 0.96). Only 7/32 (22%) melanoma patients were significantly inhibited by an extract of non-melanoma tumor. These results suggest that melanoma-associated antigens are present in soluble extracts of this tumor line. Such extracts could provide a continuing source of standard melanoma-associated antigens for purification and chemical characterization and for diagnostic and prognostic tests in patients with malignant melanoma.
黑色素瘤14是一种在化学成分明确的无血清培养基中培养的人黑色素瘤细胞系,其氯化钾提取物在36例恶性黑色素瘤患者中有19例(53%)抑制了白细胞迁移。在23例非黑色素瘤恶性肿瘤对照患者中,只有4例(17%),在25例无癌症病史的正常受试者中,只有4例(14%)受到类似抑制。在针对从黑色素瘤14供体切除的正常肌肉组织的氯化钾提取物进行测试的27例黑色素瘤患者中,只有2例受到显著抑制。I期(局限性)黑色素瘤患者和III期(广泛性)黑色素瘤患者的反应频率大致相同,但每组患者数量太少,无法进行有意义的统计分析。在一个完全自体的系统中,对黑色素瘤14供体的白细胞进行了测试,以检测黑色素瘤14组织培养细胞提取物和自体肌肉提取物,结果显示,白细胞受到黑色素瘤14组织培养提取物的特异性抑制(迁移指数=0.67),但未受到正常肌肉提取物的抑制(迁移指数=0.96)。在32例黑色素瘤患者中,只有7例(22%)受到非黑色素瘤肿瘤提取物的显著抑制。这些结果表明,黑色素瘤相关抗原存在于该肿瘤系的可溶性提取物中。此类提取物可为纯化和化学表征以及恶性黑色素瘤患者的诊断和预后测试提供持续的标准黑色素瘤相关抗原来源。